X

Trial Profile

A Phase 2 Study of PTG-300 in Non-Transfusion Dependent (NTD) and Transfusion-Dependent (TD) β-Thalassemia Subjects With Chronic Anemia

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 19 Jul 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rusfertide (Primary)
Indications Beta-thalassaemia
Focus Proof of concept; Therapeutic Use
Acronyms TRANSCEND
Sponsors Protagonist Therapeutics

Most Recent Events

20 Dec 2020 This trial has been discontinued in Italy according to European Clinical Trials Database record.
29 Jul 2020 Status changed from recruiting to completed.
10 Jul 2020 This trial has been completed in United Kingdom.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com